Monocyte-derived circulating microparticles (CD14(+), CD14(+)/CD11b(+) and CD14(+)/CD142(+)) are related to long-term prognosis for cardiovascular mortality in STEMI patients
Por:
Chiva-Blanch, G, Bratseth, V, Ritschel, V, Andersen, GO, Halvorsen, S, Eritsland, J, Arnesen, H, Badimon, L, Seljeflot, I
Publicada:
15 ene 2017
Resumen:
Background: Circulating microparticles (cMPs) have been proposed as novel biomarkers of cardiovascular disease (CVD). We aimed to investigate the prognostic relevance of cMPs for futuremajor adverse cardiovascular events (MACE) in STEMI patients.
Methods: We included 200 STEMI patients treated with percutaneous coronary intervention (PCI). One hundred patients with a primary composite end point (recurrent nonfatal acute MI, rehospitalization for heart failure, unscheduled PCI or death because of CV causes) were case-matched for sex, age, and CVD risk factors to 100 patients without a primary endpoint at the end of study follow-up (4.4 (1.4) years). cMPs from vascular cells were measured by flow cytometer at a mean of 28 h after onset of symptoms.
Results: No differences were observed in MP shedding between patients with or without a MACE at the end of the study follow-up. However, compared to patients who survived during follow-up, patients who died because of CV causes (n = 24) presented with increased total cMPs (Annexin V-AV-+), cMPs carrying tissue factor, and increased MP shedding from platelets, lymphocytes, monocytes, and activated leukocytes, and similar to 10% lower left ventricular ejection fraction (LVEF). ROC-curve analyses showed that monocyte-derived cMPs (CD14(+)/AV(+), CD11b(+)/CD14(+)/AV(+) and CD142(+)/CD14(+)/AV(+)) considered together with LVEF best predicted cardiovascular mortality.
Conclusions: Monocyte-derived cMPs assessed in the acute phase relate to the prognosis of CV death at the long term. These findings may be of clinical interest in the risk assessment of STEMI patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Filiaciones:
Chiva-Blanch, G:
Univ Oslo, Dept Cardiol, Ctr Clin Heart Res, Hosp Ulleval, Oslo, Norway
Univ Oslo, Fac Med, Oslo, Norway
CSIC, ICCC, Cardiovasc Res Ctr, Av St Antoni M Claret 167,Pavello 11, Barcelona 08025, Spain
Biomed Res Inst St Pau IIB St Pau, Cardiovasc Res Ctr ICCC, Barcelona, Spain
Bratseth, V:
Univ Oslo, Dept Cardiol, Ctr Clin Heart Res, Hosp Ulleval, Oslo, Norway
Ritschel, V:
Univ Oslo, Dept Cardiol, Ctr Clin Heart Res, Hosp Ulleval, Oslo, Norway
Univ Oslo, Fac Med, Oslo, Norway
Andersen, GO:
Univ Oslo, Hosp Ulleval, Dept Cardiol, Oslo, Norway
Halvorsen, S:
Univ Oslo, Fac Med, Oslo, Norway
Univ Oslo, Hosp Ulleval, Dept Cardiol, Oslo, Norway
Eritsland, J:
Univ Oslo, Hosp Ulleval, Dept Cardiol, Oslo, Norway
Arnesen, H:
Univ Oslo, Dept Cardiol, Ctr Clin Heart Res, Hosp Ulleval, Oslo, Norway
Univ Oslo, Fac Med, Oslo, Norway
Badimon, L:
CSIC, ICCC, Cardiovasc Res Ctr, Av St Antoni M Claret 167,Pavello 11, Barcelona 08025, Spain
Seljeflot, I:
Univ Oslo, Dept Cardiol, Ctr Clin Heart Res, Hosp Ulleval, Oslo, Norway
Univ Oslo, Fac Med, Oslo, Norway
Univ Oslo, Hosp Ulleval, Dept Cardiol, Oslo, Norway
Open Access
|